Copy to clipboard 
Twinsight, developer of orthopedic surgical planning software, completed its seed fundraising round, raising a total of €1.6 million (USD $1.8 million). The round positions the company to build on its recent FDA 510(k) clearance for SurgiTwin 3D and establish a strong commercial foothold in the U.S. while finalizing the development of SurgiTwin 4D and securing FDA clearance for the new solution.
In addition, the company appointed two new members to its Board of Directors: Cyrille Fleury and David Anderson.
Cyrille Fleury brings more than 20 years of operational and strategic leadership experience. As former CEO of Groupe Menix, he drove strong growth, launched AI-driven innovations, and led international expansion—including the opening of a US subsidiary—culminating in the successful sale of SERF to Stryker. He also held senior leadership roles at Tornier and Wright Medical.
A global marketing and business development executive in the medical device and biologics industry, David Anderson brings a consistent track record of growing revenues through the application of marketing fundamentals and effective leadership. He is recognized for strategic thinking from organization to product, and for creating value through M&A.
“We are proud to count these expert surgeons among our investors,” said Twinsight CEO Mathieu Rimaud. “Their support, alongside the continued trust of our individual investors, sends a strong signal that SurgiTwin 3D already responds to a real market need. This funding is decisive for Twinsight: It will allow us to fully capitalize on our FDA clearance and take our technology to surgeons across the United States. 2026 will be the year we officially enter the US market. The funds raised will also support continued development towards clearance of the next version of our software: SurgiTwin 4D, which will bring our innovative biomechanical digital twin concept to the next level.”
Source: Twinsight
Twinsight, developer of orthopedic surgical planning software, completed its seed fundraising round, raising a total of €1.6 million (USD $1.8 million). The round positions the company to build on its recent FDA 510(k) clearance for SurgiTwin 3D and establish a strong commercial foothold in the U.S. while finalizing the development of SurgiTwin...
Twinsight, developer of orthopedic surgical planning software, completed its seed fundraising round, raising a total of €1.6 million (USD $1.8 million). The round positions the company to build on its recent FDA 510(k) clearance for SurgiTwin 3D and establish a strong commercial foothold in the U.S. while finalizing the development of SurgiTwin 4D and securing FDA clearance for the new solution.
In addition, the company appointed two new members to its Board of Directors: Cyrille Fleury and David Anderson.
Cyrille Fleury brings more than 20 years of operational and strategic leadership experience. As former CEO of Groupe Menix, he drove strong growth, launched AI-driven innovations, and led international expansion—including the opening of a US subsidiary—culminating in the successful sale of SERF to Stryker. He also held senior leadership roles at Tornier and Wright Medical.
A global marketing and business development executive in the medical device and biologics industry, David Anderson brings a consistent track record of growing revenues through the application of marketing fundamentals and effective leadership. He is recognized for strategic thinking from organization to product, and for creating value through M&A.
“We are proud to count these expert surgeons among our investors,” said Twinsight CEO Mathieu Rimaud. “Their support, alongside the continued trust of our individual investors, sends a strong signal that SurgiTwin 3D already responds to a real market need. This funding is decisive for Twinsight: It will allow us to fully capitalize on our FDA clearance and take our technology to surgeons across the United States. 2026 will be the year we officially enter the US market. The funds raised will also support continued development towards clearance of the next version of our software: SurgiTwin 4D, which will bring our innovative biomechanical digital twin concept to the next level.”
Source: Twinsight
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
